Busiwire
Research and Markets: Independent Forecasts and Competitive Intelligence on Thailand's Pharmaceuticals and Healthcare Industry
Wednesday March 11, 10:17 PM
Research and Markets (http://www.researchandmarkets.com/research/05ec68/thailand_pharmaceu)
has announced the addition of the "Thailand
Pharmaceuticals and Healthcare Report Q1 2009" report to their
offering.
In the Business Environment Ranking matrix for Q109, Thailand has
significantly improved its position, now ranked ninth out of the15
regional markets surveyed in the Asia Pacific region, up from a shared
12th in the previous quarter. Thailand's growing and ageing population
represents a substantial commercial opportunity for drugmakers, although
its precarious political climate and the controversial compulsory
licensing scheme are deterring foreign investment and involvement in its
pharmaceutical market, with a potential to lead to international
sanctions.
Nevertheless, by September 2008, none of the six pharmaceutical
compulsory licences sought by the Thai government had received formal
certification. The situation was blamed on legal hurdles, as Thailand's
Council of State is still considering processes related to the official
granting and working of the licences. However, the Government
Pharmaceutical Organisation (GPO) is already producing and marketing the
heart drug Plavix (clopidogrel), which has not yet been approved by the
compulsory licensing scheme. In addition, the GPO intends to follow up
of the success of Plavix with another medicine obtained via a compulsory
licence, the anticancer agent Taxotere (docetaxel), which has been
imported from India and is to go on sale imminently. While the GPO also
announced that it expects sales growth to decrease significantly over
the next financial year (FY) owing to a challenging operating
environment, its FY08 (year ending September 30 2008) sales were 14%
higher year-on-year (y-o-y).
Similarly, despite Thailand's current economic and political turmoil,
Bayer Schering Pharma stated that it expects the country's
pharmaceutical market to continue its promising growth trajectory. This
is mainly due to the government's strong commitment to providing public
healthcare, but also the buoyant medical tourism sector. Moreover, the
German drugmaker expects its business 'to grow in line with the market
or even over the market average'.
Companies Mentioned:
Pfizer
Sanofi-Aventis
Novartis
GlaxoSmithKline
Merck & Co
Domestic Manufacturer Profiles
Siam Pharmaceutical
Government Pharmaceutical Organisation (GPO)
Biolab Co
Thai Meiji Pharmaceutical Co
For more information visit http://www.researchandmarkets.com/research/05ec68/thailand_pharmaceu
Contact:Research and MarketsLaura Wood, Senior Manager, press@researchandmarkets.comU.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
Next Article: Research and Markets: Illustrative Food and Drink Report Thailand Q1 2009
Previous article: Research and Markets: Thai Petroleum Pipeline Company Limited Detailed Analysis and Forecasts of Pipelines
Top Headlines
Fairfax NZ CEO to step down
Friday March 13, 08:00 PM - AAP
Fairfax Media has lost another of its executives, with the resignation of its New Zealand chief executive Joan Withers. .. Read More
Commission approves line upgrades
Friday March 13, 07:57 PM - NZPA
The Electricity Commission has given the green light to improvements to the Wellington and Wairarapa grids by Transpower. .. Read More
RPI still trying to secure funding
Friday March 13, 07:50 PM - NZPA
Rural Portfolio Investments Ltd (RPI) is still trying to secure funding for a looming redemption of redeemable preference sha .. Read More
Calculators
Copyright © 2009 Yahoo! All rights reserved.
Yahoo!Xtra: A Yahoo!7/Telecom New Zealand Company.